Humacyte, Inc. (HUMA) closed the most recent trading day at $0.78, moving -2.32% from the previous trading session. This change lagged the S&P 500's 0.79% gain on the day. Meanwhile, the Dow ...

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day's close.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

Humacyte’s fair value estimate has been reset from US$7.86 to US$2.05, marking a sharp recalibration of how analysts are ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an ...

In the latest trading session, Humacyte, Inc. (HUMA) closed at $5.17, marking a -1.34% move from the previous day. This change lagged the S&P 500's daily loss of 0.16%. Elsewhere, the Dow saw an ...

The latest price target for Humacyte (NASDAQ:HUMA) was reported by TD Cowen on June 17, 2026. The analyst firm set a price target for $1.25 expecting HUMA to rise to within 12 months (a possible 99.65 ...

Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were $0.5 million in 2026 compared to ...

Laboratory and preclinical models demonstrate biovascular pancreas platform technology may provide method to transplant islet cells that produce insulin in Type 1 diabetes patients Data presented at ...

On June 10, 2026, Humacyte reported positive top-line interim results from its Phase 3 V012 trial evaluating its acellular tissue engineered vessel (ATEV) for dialysis access in female patients with ...

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...